Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike glycoprotein of SARS-CoV-2 (Beta variant) (S protein)
- Target
- S protein
- Molecular classification
- Viral fusion protein, Class I viral fusion protein, Membrane glycoprotein
01
Overview
The Spike glycoprotein of SARS-CoV‑2 is a large, trimeric class I viral fusion protein that protrudes from the surface of coronavirus particles. It mediates attachment to host cells by specifically binding to the angiotensin-converting enzyme 2 (ACE2) receptor through its receptor-binding domain. The Beta variant (lineage B.1.351) contains key amino acid substitutions—K417N, E484K, N501Y—in its receptor-binding domain that increase infectivity and confer partial resistance to neutralizing antibodies generated against earlier strains. The spike is heavily glycosylated and undergoes proteolytic cleavage at specific sites during maturation and entry processes. As it plays an essential role in viral entry and is highly immunogenic, it serves as both a major therapeutic target for monoclonal antibody drugs and the principal antigen in most COVID‑19 vaccines.[1][2][3][4]
- Other names
- Spike proteinS glycoproteinSARS-CoV-2 spike proteinS protein (Beta variant)Surface glycoprotein
02
Mechanism of action
Neutralization of virus by blocking ACE2 binding site on spike RBD[1][3] Inhibition of conformational changes required for membrane fusion – Induction of protective immune responses via vaccination
03
Biological functions
Mediates viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor[1][3][4]Facilitates membrane fusion between virus and host cell[3][4]Major target for neutralizing antibodies and immune response[3]
04
Disease associations
Infection (COVID‑19)[1][3]
05
Safety considerations
Immune escape due to mutations in Beta variant’s RBD region leading to reduced efficacy of some monoclonal antibodies and vaccines[1]Potential risk of antibody-dependent enhancement is a theoretical concern but not observed with current COVID‑19 vaccines
06
Interacting drugs
Monoclonal antibodies targeting the spike RBD or other epitopes (e.g., casirivimab, imdevimab, sotrovimab)
1 more in the full profile.
07
Biomarkers
Presence of anti-spike IgG/IgM antibodies as markers for infection or vaccine response[3]Mutations in spike gene as markers for variant identification and therapeutic selection
Beyond the preview
Go deeper on Spike glycoprotein of SARS-CoV-2 (Beta variant) (S protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike glycoprotein of SARS-CoV-2 (Beta variant) (S protein).